Dyne Therapeutics (DYN) Institutional Ownership
13F filers reported holding 25.2% of Dyne Therapeutics (DYN) shares as of Sep 30, 2026, across 134 filers.
- Held by 13F filers
- 25.2%
- Sep 30, 2026
- 13F filers
- 134
- quarter ended Sep 30, 2026
- 13F value
- $761.9M
- 47.3M shares
- Quarter's fund flow
- Mild accumulation
- 23 new · 12 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Oct 20, 2026 | Kerr Douglas | Head of R&D and CMO | Acquired · Grant / award | 8,000 | — | ↗ |
| Oct 20, 2026 | Kerr Douglas | Head of R&D and CMO | Acquired · Grant / award | 12,000Stock option (right to buy) | — | ↗ |
| Oct 2, 2026 | Posner Brian S | director | Acquired · Open-market buy | 2,500 | $16.00 | ↗ |
| Sep 8, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Disposed · Open-market sale | 185 | $18.88 | ↗ |
| Sep 8, 2026 | Kerr Douglas | Chief Medical Officer | Disposed · Open-market sale | 1,290 | $18.88 | ↗ |
| Sep 8, 2026 | Cox John | CEO & President | Disposed · Open-market sale | 5,658 | $18.88 | ↗ |
| Sep 4, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Disposed · Open-market sale | 900 | $24.35 | ↗ |
| Sep 4, 2026 | Kerr Douglas | Chief Medical Officer | Disposed · Open-market sale | 3,745 | $24.35 | ↗ |
| Aug 14, 2026 | Rhodes Jason P | director | Disposed · Open-market sale | 1,359,674 | $25.00 | ↗ |
| Aug 14, 2026 | Rhodes Jason P | director | Disposed · Open-market sale | 478,377 | $25.00 | ↗ |
| Aug 14, 2026 | Rhodes Jason P | director | Disposed · Open-market sale | 322,465 | $25.00 | ↗ |
| Aug 13, 2026 | Friedl-Naderer Johanna | Chief Commercial Officer | Disposed · Open-market sale | 226 | $26.28 | ↗ |
| Aug 13, 2026 | Kerr Douglas | Chief Medical Officer | Disposed · Open-market sale | 1,556 | $26.28 | ↗ |
| Aug 13, 2026 | Lucera Erick | Chief Financial Officer | Disposed · Open-market sale | 1,797 | $26.28 | ↗ |
| Aug 13, 2026 | Rhodes Jason P | director | Disposed · Open-market sale | 268,354 | $26.20 | ↗ |
| Aug 13, 2026 | Rhodes Jason P | director | Disposed · Open-market sale | 94,415 | $26.20 | ↗ |
| Aug 13, 2026 | Rhodes Jason P | director | Disposed · Open-market sale | 63,643 | $26.20 | ↗ |
| Aug 13, 2026 | Cox John | CEO & President | Disposed · Open-market sale | 4,986 | $26.28 | ↗ |
| Jul 27, 2026 | Kersten Dirk | director | Disposed · Open-market sale | 256,072 | $25.50 | ↗ |
| Jul 27, 2026 | Kersten Dirk | director | Disposed · Open-market sale | 5,388 | $26.04 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Dyne Therapeutics do institutions hold?
13F filers reported holding 25.2% of Dyne Therapeutics' shares as of Sep 30, 2026, across 134 filers.
How many 13F filers hold Dyne Therapeutics?
Dyne Therapeutics was held by 134 13F filers as of Sep 30, 2026.
Not investment advice.

